Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: J Allergy Clin Immunol. 2015 Jun 1;136(4):962–970.e1. doi: 10.1016/j.jaci.2015.04.029

Table 3. Adverse events.

Adverse events Active Placebo p-value

Number of AEs reported per subject – median (range) 4 (0-34) 5 (0-19) 0.88

Type of AE:
 GI 61 (23%) 28 (23%) 1
 Cutaneous 17 (6.4%) 6 (4.9%) 0.65
 Respiratory 56 (21.1%) 22 (18%) 0.59
 Ocular 4 (1.5%) 1 (0.8%) 1
 Sinusitis 4 (1.5%) 2 (1.6%) 1
 Pharyngitis 15 (5.7%) 13 (10.7%) 0.09
 Headache 29 (11%) 8 (6.6%) 0.20
 Lab abnormality 11 (4.2%) 3 (2.5%) 0.56
 Food allergic reaction 28 (10.6%) 17 (13.9%) 0.39
 SCIT reaction for AR 0 3 (2.5%)* 0.03
 Fever, no other symptoms 2 (0.8%) 1 (0.8%) 1
 Other** 38 (14.3%) 18 (14.8%) 1

Severity:
 Mild 250 113
 Moderate 15 9 0.50
 Severe 0 0

Relatedness:
 Definitely 1 0
 Probably 7 0
 Possibly 45 18 0.66
 Unrelated 212 104 0.26
*

Reported for a single subject

**

Other symptoms included: tooth infection, yeast infection, neck pain, orthopedic injury, ingrown toenail, ingrown hair, epistaxis, general malaise, insect bite, cold sore, otitis externa, black eye, hot flashes, sun sensitivity, difficulty sleeping, UTI, salivary gland infection, fatigue, concussion, pain from braces, thrush